

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India  
Ministry of Chemicals and Fertilizers  
Department of Pharmaceuticals  
National Pharmaceutical Pricing Authority

New Delhi, the 14<sup>th</sup> February, 2017

ORDER

**S.O. 445(E)** In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

**Table**

<b>Sl. No.</b>	<b>Name of the Scheduled Formulation / Brand Name</b>	<b>Strength</b>	<b>Unit</b>	<b>Manufacturer &amp; Marketing Company respectively</b>	<b>Retail Price (Rs.)</b>
<b>(1)</b>	<b>(2)</b>	<b>(3)</b>	<b>(4)</b>	<b>(5)</b>	<b>(6)</b>
1.	Cyblex M 30 XR tablet	Each uncoated bilayered tablet contains: Metformin HCL 500mg (as extended release) Gliclazide 30mg	10 Tablets	M/s Eris Life Sciences Pvt. Ltd.	49.60
2.	Cyblex M 40 tablet	Each uncoated tablet contains: Gliclazide 40mg Metformin HCl 500mg	10 Tablets	M/s Eris Life Sciences Pvt. Ltd.	45.40
3.	Cyblex M 60 XR tablet	Each uncoated bilayered tablet contains: Gliclazide 60mg (as extended release) Metformin HCl 500mg (as extended release)	10 Tablets	M/s Eris Life Sciences Pvt. Ltd.	79.80
4.	Cyblex M 80 tablet	Each uncoated tablet contains: Gliclazide 80mg Metformin HCl 500mg	10 Tablets	M/s Eris Life Sciences Pvt. Ltd.	50.93
5.	Cyblex MV 80.2 (0.2/500/80) tablet	Each uncoated tablet contains: Metformin HCL 500mg Gliclazide 80mg Voglibose 0.2mg	10 Tablets	M/s Eris Life Sciences Pvt. Ltd.	113.70

6.	Cyblex MV 80.3 (0.3/500/80) tablet	Each uncoated tablet contains: Metformin HCL 500mg Gliclazide 80mg Voglibose 0.3mg	10 Tablets	M/s Eris Life Sciences Pvt. Ltd.	115.80
----	---------------------------------------	--	---------------	-------------------------------------	--------

Note:

(a) The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail prices are applicable only to the manufacturer / marketer as mentioned above for generic / any brand of the same composition / strength of the subject formulations, subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

(f) The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(h) Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand(s) superseded.

PN/173/41/2017/F

F. No. 8(41)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director